Advancements in Rare Pediatric Disease Treatments: Updates from Biopharmaceutical Companies
Update: 2025-09-30
Description
Lantern Pharma Inc. prepares for a clinical trial targeting a rare pediatric disease with its investigational therapy LP-184/STAR-001, while City of Hope explores the use of scorpion venom in fighting brain cancer. Additionally, Tonix Pharmaceuticals Holding Corp. advances TNX-2900 for Prader-Willi Syndrome, and Soligenix Inc. expands its European Medical Advisory Board for a Phase 3 trial of HyBryte in cutaneous T-cell lymphoma. Exciting developments are underway in the biopharmaceutical industry to address unmet medical needs in various conditions.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
